Selected Publications

Niswander LM, McClellan S, Shraim R, Falkenstein CD, Yarnell M, Meadows CA, Fry TJ, Tasian SK: Combinatorial Immunotherapeutic and Targeted Kinase Inhibition Approach in KMT2A-Rearranged Acute Lymphoblastic Leukemia. Abstract for oral presentation at the International Society of Pediatric Oncology (SIOP) annual meeting October 2023.

Niswander LM, Chung P, Diorio C, and Tasian SK: Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax. Haematologica Online ahead of print, April 2023.

Niswander LM*, Graff ZT*, Chien CD*, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK#, Fry TJ#: Potent preclinical activity of FLT3-directed CAR T cell immunotherapy against FLT3-mutant AML and KMT2A-rearranged ALL. Hematologica 108(2): 457-471, February 2023.

Niswander LM, Chung P, Diorio C, Tasian SK: Clinical Experience with Azacitidine and Venetoclax +/- Gemtuzumab in Pediatric Patients with Relapsed or Refractory Acute Leukemias: A Report from the Children’s Hospital of Philadelphia. Poster Presentation at the American Society of Hematology Annual Meeting Dec 2022.

Niswander LM, Chung P, Diorio C, Tasian SK: Single-Institution Clinical Experience with Azacitidine and Venetoclax +/- Gemtuzumab in Pediatric Patients with Relapsed or Refractory Acute Leukemias. Poster presentation at Children’s Oncology Group Fall Meeting Sept 2022.

Niswander LM, Chukinas JA, Graff Z, Bagashev A, Leach L, Fry TJ, and Tasian SK: Targeting of FLT3 with Chimeric Antigen Receptor T Cell Immunotherapy and Tyrosine Kinase Inhibition in High-Risk Pediatric Leukemias. Abstract for oral presentation at the American Society of Hematology Annual Meeting December 2021.

Qin H, Yang L, Chukinas JA, Shah NN, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor NA, Tasian SK, Fry TJ: Systematic Preclinical Evaluation of CD33-Directed Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia Defines Optimized Construct Design. Journal for ImmunoTherapy of Cancer 9: e003149, 2021.

Saunders J, Niswander LM, McGrath KM, Koniski A, Catherman SC, Ture SK, Medhora M, Kingsley PD, Calvi LM, Williams JP, Morrell CN, and Palis J: Long-acting PGE2 and lisinopril mitigate H-ARS. Radiation Research 196(3): 284-296, 2021.

Niswander LM*, Loftus JP*, Lainey E, Caye-Eude A, Pondrom M, Hottman DA, Iacobucci I, Mullighan CG, Jain N, Konopleva M, Cave G, Baruchel A, Rohrlich PS, and Tasian SK: Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica 106(10): 2763-2767, 2021.

Loftus JP, Yahiaoui A, Brown PA, Niswander LM, Bagashev A, Wang M, Schauf A, Tannheimer, Tasian SK: Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. Haematologica 106(4): 1067 - 1078, 2020.